According to Duramed, LoSEASONIQUE is the latest addition to the extended-cycle oral contraceptive category introduced by the company in 2003, which includes Seasonique.
The Duramed contraceptive sales force has started introducing LoSEASONIQUE to healthcare providers. In addition, Duramed will launch a marketing campaign to educate healthcare providers and patients about the product.
On the LoSEASONIQUE extended-cycle regimen, women take combination tablets containing 0.10mg levonorgestrel/0.02mg of ethinyl estradiol daily for 84 consecutive days, followed by 0.01mg ethinyl estradiol tablets for seven days. The regimen is designed to reduce the number of withdrawal bleeding periods from 13 to four per year, said Duramed.
Amy Niemann, general manager and senior vice president of women’s health at Duramed, said: “The launch of LoSEASONIQUE demonstrates our commitment to providing women who are seeking oral contraception with even more options to have fewer scheduled periods. Women want options when it comes to birth control and we will continue to provide innovative products to meet their needs.”